HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Iichiro Shimomura Selected Research

Hypoglycemic Agents (Hypoglycemics)

12/2022Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
6/2022Improvement of beta-cell function in conjunction with glycemic control after medical nutrition therapy in newly-diagnosed type 2 diabetes mellitus.
1/2022Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study.
1/2022The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control.
1/2021Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
11/2020Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan.
1/2019Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype.
1/2017Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus.
3/2016Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
9/2014Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Iichiro Shimomura Research Topics

Disease

115Type 2 Diabetes Mellitus (MODY)
01/2024 - 07/2002
69Obesity
11/2023 - 04/2002
65Insulin Resistance
06/2022 - 05/2002
47Atherosclerosis
12/2023 - 09/2002
37Cardiovascular Diseases (Cardiovascular Disease)
02/2023 - 03/2007
32Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2023 - 07/2002
24Hypertension (High Blood Pressure)
03/2024 - 01/2003
23Type 1 Diabetes Mellitus (Autoimmune Diabetes)
10/2023 - 01/2010
22Neoplasms (Cancer)
01/2022 - 01/2004
22Hypoadiponectinemia
01/2017 - 09/2002
20Inflammation (Inflammations)
01/2022 - 09/2006
19Hyperglycemia
01/2022 - 03/2005
18Diabetes Mellitus
03/2024 - 01/2003
18Body Weight (Weight, Body)
01/2024 - 09/2003
16Hypoglycemia (Reactive Hypoglycemia)
04/2022 - 01/2012
14Coronary Artery Disease (Coronary Atherosclerosis)
04/2022 - 04/2002
13Glucose Intolerance
11/2023 - 01/2009
12Abdominal Obesity
07/2021 - 01/2003
11Cushing Syndrome
11/2023 - 01/2013
11Dyslipidemias (Dyslipidemia)
10/2023 - 01/2003
11Carotid Artery Diseases
01/2023 - 11/2005
10Hypoxia (Hypoxemia)
01/2024 - 10/2006
10Hypertriglyceridemia
09/2022 - 06/2003
8Diabetic Retinopathy (Retinopathy, Diabetic)
06/2021 - 07/2010
7Hyperaldosteronism (Conn Syndrome)
03/2024 - 01/2017
7Hyperinsulinism (Hyperinsulinemia)
03/2022 - 10/2002
7Heart Failure
03/2021 - 09/2005
6COVID-19
05/2024 - 12/2021
6Fibrosis (Cirrhosis)
05/2023 - 09/2007
6Weight Loss (Weight Reduction)
01/2023 - 03/2012
6Atherosclerotic Plaque (Atheroma)
11/2022 - 07/2007
6Diabetic Nephropathies (Diabetic Nephropathy)
09/2022 - 01/2013
5Diabetes Complications
10/2023 - 01/2019
5Non-alcoholic Fatty Liver Disease
07/2023 - 05/2005
5Peripheral Arterial Disease
04/2022 - 07/2012
5Pituitary Neoplasms (Pituitary Adenoma)
12/2019 - 01/2012
5Chronic Limb-Threatening Ischemia
07/2014 - 12/2010
5Mason-Type Diabetes
12/2008 - 04/2005
5Vascular Diseases (Vascular Disease)
04/2008 - 04/2002
4Albuminuria
10/2023 - 09/2007
4Liver Diseases (Liver Disease)
02/2023 - 10/2007
4Pancreatitis
09/2022 - 01/2010
4Chronic Renal Insufficiency
04/2022 - 01/2020
4Hyperuricemia
04/2022 - 06/2011

Drug/Important Bio-Agent (IBA)

109AdiponectinIBA
05/2024 - 05/2002
82Glucose (Dextrose)FDA LinkGeneric
03/2024 - 10/2002
65Insulin (Novolin)FDA Link
11/2023 - 07/2002
25AdipokinesIBA
05/2024 - 04/2002
25Proteins (Proteins, Gene)FDA Link
09/2023 - 05/2002
18Triglycerides (Triacylglycerol)IBA
06/2023 - 06/2003
17Messenger RNA (mRNA)IBA
11/2022 - 04/2002
17Biomarkers (Surrogate Marker)IBA
05/2022 - 02/2011
13Hypoglycemic Agents (Hypoglycemics)IBA
12/2022 - 06/2005
13Sitagliptin Phosphate (Januvia)FDA Link
01/2018 - 01/2012
12Glucagon (Glukagon)FDA Link
05/2022 - 01/2009
11AlbuminsIBA
10/2023 - 09/2007
11CholesterolIBA
11/2022 - 07/2003
11HDL CholesterolIBA
01/2021 - 11/2005
10LipidsIBA
10/2023 - 02/2011
10Hemoglobins (Hemoglobin)IBA
10/2023 - 06/2011
10Dipeptidyl-Peptidase IV InhibitorsIBA
01/2023 - 01/2013
10Hormones (Hormone)IBA
03/2021 - 10/2002
10HDL LipoproteinsIBA
01/2021 - 02/2007
9Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
10/2023 - 12/2011
8Sodium-Glucose Transporter 2 InhibitorsIBA
01/2023 - 01/2015
8Glucagon-Like Peptide 1 (GLP 1)IBA
04/2022 - 12/2011
8Reactive Oxygen Species (Oxygen Radicals)IBA
04/2022 - 01/2009
8LigandsIBA
01/2022 - 06/2003
8Blood Glucose (Blood Sugar)IBA
01/2020 - 12/2010
8EnzymesIBA
05/2019 - 03/2006
8Pioglitazone (Actos)FDA Link
01/2019 - 06/2005
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2017 - 07/2002
7Hydrocortisone (Cortisol)FDA LinkGeneric
11/2023 - 01/2013
7alogliptinIBA
01/2023 - 01/2013
7Sucrose (Saccharose)IBA
01/2021 - 01/2003
7LeptinIBA
01/2011 - 05/2002
6Adrenocorticotropic Hormone (ACTH)FDA Link
03/2024 - 07/2013
6AldosteroneIBA
03/2024 - 01/2017
6LiraglutideFDA Link
01/2024 - 12/2011
6Indicators and Reagents (Reagents)IBA
11/2023 - 09/2011
6Sodium-Glucose Transport ProteinsIBA
01/2023 - 01/2015
66- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
01/2023 - 10/2017
6GlucocorticoidsIBA
12/2019 - 03/2012
6CytokinesIBA
01/2019 - 09/2006
5Transcription Factors (Transcription Factor)IBA
01/2024 - 02/2014
5Uric Acid (Urate)IBA
02/2023 - 07/2012
5H-cadherin (T-cadherin)IBA
12/2022 - 01/2017
5C-PeptideIBA
01/2022 - 08/2017
5Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA
12/2021 - 10/2009
5Metformin (Glucophage)FDA LinkGeneric
12/2021 - 01/2012
5glimepiride (Amarel)FDA LinkGeneric
01/2020 - 06/2005
4SodiumIBA
03/2024 - 10/2017
4Endoplasmic Reticulum Chaperone BiPIBA
09/2023 - 04/2007
4Xanthine DehydrogenaseIBA
07/2023 - 09/2013
4purineIBA
07/2023 - 09/2013
4Insulin Glargine (Lantus)FDA Link
02/2023 - 01/2012

Therapy/Procedure

46Therapeutics
02/2023 - 07/2003
30Glycemic Control
10/2023 - 12/2010
5Transplantation
12/2019 - 10/2009
4Bariatric Surgery
11/2023 - 01/2022